Claim Ledger
42% answered
Did management answer the analysts?
12 analyst questions audited, 5 evaded or deflected.
View Claim Ledger →Cohance Lifesciences Ltd — Q4 FY26
Cohance Lifesciences reported FY26 revenue of ₹22.68B, down 13% YoY, with adjusted EBITDA margin of 21% (standalone 24.6%).
bearish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Cohance Lifesciences reported FY26 revenue of ₹22.68B, down 13% YoY, with adjusted EBITDA margin of 21% (standalone 24.6%). The CDMO segment was hit by destocking of two large commercial molecules (~₹260Cr impact) and delayed reloads, while API Plus declined 8% due to shipment delays and Nacharam site disruption. Specialty Chemicals fell 2.1% on program phasing. Management guided Q1 FY27 as the low point, with recovery from H2 driven by order conversion, new commercial launches (two molecules already commercialized, two more expected), and a strengthened phase 3 pipeline of 10 programs. Key risks include Middle East logistics cost inflation (100-150bps gross margin impact in Q1), delayed recovery of destocked molecules, and execution at NJ Bio (breakeven >2 years away). New CEO Omar Gora is focused on strategic blueprint, operational rigor, and deepening customer relationships.
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Delayed recovery of destocked molecules
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Phase 3 Pipeline
10 programs
+1 program YoY
Added one small molecule, one ADC, and one oligonucleotide program; two moved to commercial.
Active CDMO Projects
140+
flat YoY
Includes development and commercial programs across small molecules, ADCs, and oligonucleotides.
API Top 15 Leadership Products
~50% of API revenue
stable YoY
Eight of top 10 molecules hold leadership positions; portfolio remains differentiated.
R&D Spend as % of Revenue
16.2%
flat YoY
Continued investment in ADC and oligonucleotide capabilities.
What Changed vs Last Quarter
NEW
Q1 FY27 to be low point for revenue and EBITDA
Revenue and EBITDA in Q1 FY27 expected to be weak due to revenue schedules skewed to H2, logistics cost inflation, and higher operating costs.
NEW
Capex of ~₹3B in FY27
Capital expenditure focused on ADC and oligonucleotide manufacturing infrastructure and quality systems.
NEW
Gross margin impact of 100-150 bps in Q1 FY27 from Middle East logistics
Escalation in logistics and input costs due to Middle East geopolitical situation will impact gross margins, mainly in API Plus business.
UPDATED
Growth to return from H2 FY27
Recovery expected in second half of FY27, driven by order conversion, reloads, and improving utilization across the platform.
DROPPED
FY26 revenue decline of early-to-mid double digits
Management revised FY26 revenue outlook to reflect an early-to-mid double-digit decline due to timing and product mix issues.
DROPPED
Four phase 3 molecules expected to move to commercial supply in FY27
Four molecules across ADHD, antibiotic, and oncology are expected to enter commercial supply in FY27; two already have USFDA approval.
DROPPED
$10 million CGMP US-based expansion for ADC
A $10 million CGMP expansion is underway to enable full ADC supply capability up to phase 2B by FY27.
NEW RISK
Delayed recovery of destocked molecules
Two large commercial molecules under destocking may not return as expected; management declined to quantify value, creating uncertainty.
NEW RISK
Middle East logistics cost inflation
Geopolitical tensions have increased freight and raw material costs, expected to impact gross margins by 100-150 bps in Q1 FY27.
NEW RISK
NJ Bio profitability timeline extended
NJ Bio's US facility expansion and bio conjugation capabilities will take >2 years to reach breakeven, delaying consolidated margin recovery.
NEW RISK
Customer concentration in CDMO
Historical reliance on a few molecules led to revenue volatility; diversification is improving but still a risk.
RISK GONE
Further destocking or patent expiry impact on commercial products
Two large commercial products faced earlier-than-expected volume recalibration due to patent expiry and inventory normalization; similar risks exist for other mature products.
RISK GONE
Nacharam facility warning letter may delay US market recovery
The Nacharam formulation site received a warning letter; US shipments remain suspended, and remediation may take time, impacting ~₹55 crore in deferred shipments.
RISK GONE
Biotech funding environment continues to pressure subsidiary and ADC demand
Slower decision-making and contract renewals due to biotech funding constraints have muted subsidiary performance and ADC near-term demand.
RISK GONE
Commercial ramp-up of phase 3 molecules may be slower than expected
Management acknowledged that the pace of commercial ramp-up has been slower than anticipated due to customer launch sequencing and cautious initial scale.
Fast read
Guidance and risk preview
Revenue and EBITDA in Q1 FY27 expected to be weak due to revenue schedules skewed to H2, logistics cost inflation, and higher operating costs.
Two large commercial molecules under destocking may not return as expected; management declined to quantify value, creating uncertainty.
View Risks →